Member Info for Diplomat65

So you reckon a minimum of £1 net profit then Pigster? What maximum price do you think Avacta/BBI/Abingdon/ODX would demand from HMG?

While we wait to hear all about it from Boris on 22nd February, perhaps we can speculate about the value to Avacta of being a contributor to the Sovereign LFD.
Excalibur Healthcare Services operating from offices in Orange St, London WC2 offer what I believe to be Innova's poor quality, stop-gap product for £6:25 + VAT and delivery for boxes of 500 test kits.

https://rapidantigentestkit.co.uk/

If that sets the price point then stripping away packaging, buffer solution, pipettes etc assume £5 for the complete cassette. This product is a result of Avacta (Affimer) BBI (nitrocellulose strip?) and Abingdon cassette assembly (?) each wanting their cost recovered plus margin. If shared equally each partner can expect around £1.60 per LFD less cost of sale less operating expense contribution I'm going to assume a net profit of £1. I'd settle for that if I were on Avacta's BOD, what do you guys think?
Well, I've nothing else to do so thought I'd share my musing with you all on another slow day.
Have a safe week-end all LTH.

ITV’s Tonight programme on COVID Testing undermined confidence in lateral flow devices generally rather than in Innova’s appallingly inaccurate Chinese product. Whenever the Sovereign LFD is ready to be rolled out, the need for some powerful evidence proving the reliability and accuracy of the (hopefully) Affimer-based LFD will have to be shared widely in the public domain if the Nation is to not only use it, but trust it.

My partner works for NHS and follows the exact same routine with the exact same kit - Innova. It’s a stop-gap LFD until the Sovereign supply managed by PA Consulting comes on stream. A little more patience needed for astounding rewards!!

Speaking during a visit to a mosque in Birmingham to promote the safety of vaccination to a wary BAME community Robert Jenrick said in an interview that the vaccines were “safe and efficacious having been judged by the MRSA”.

Let’s hope that dreadful bacteria has no role in the Sovereign LFD being rolled out - lol. What has happened to our leadership?
Robert Jenrick is a British Conservative Party politician serving as Secretary of State for Housing, Communities and Local Government

Patrick Vallance just referred to anti-viral drugs becoming available later this year. Affimer-based therapeutics from Avacta?

Fan of Lucy then Doh?

Manc_NW - no idea but also checked Stock Exchange, Yahoo Finance, Stockopedia and Sharecast and all show closing price of 140

This site quotes “Share Price 140”, Investing.com and ADVFN also showing 140. HL are showing 130 so who knows!

Will 140 be tomorrow’s opening price? Odd finish to the day’s price action.

Boris said and I quote:
“Even if we achieve this goal (vaccinating the 4 most vulnerable groups) there remains a two three week lag from getting the jab to receiving immunity . . . “
What is that based on? As far as I have been able to understand from all I’ve listened to and read, none of the scientific community experts have claimed the vaccines offer immunity, only the expectation that the severity of infection will be reduced!

DOH85 - thank you for your prompt reply and for the very useful link. Happy New Year ??

DOH85 - you wrote . . .

“ when Avacta release an RNS it’s always one of the if not the most read RNSs.”

Where can I find the website that measures the number of readers generated by an RNS? Thanks in advance.

This looks like a real breakthrough in home testing though manufacturing appears limited - https://www.ellumehealth.com/2020/12/15/fda-authorizes-ellume-covid-19-home-test-as-first-over-the-counter-fully-at-home-diagnostic-test/?utm_campaign=Medical%20Technology&utm_content=149602507&utm_medium=social&utm_source=linkedin&hss_channel=lcp-9165

. . . but seriously? Why are you here? It’s Christmas Day ffs! Spend your time with a loved one - and “No” this Board doesn’t count!

To extend your racing car analogy, if Avacta is the only car to make it to the finish line it doesn’t matter how many laps behind their car is when it enters the race. From what I have read the other competitors’ cars are suffering all manner of performance problems and pit stops while others have simply withdrawn. Though to be honest, Avacta have never behaved like they’re in a race rather appearing to have a strong, unshakeable focus on the finish line. Brrrm, brrrm, brrrm!!

Presumably the viral load of saliva is proving inadequate or at least questionable for definitive testing versus nasal swabbing? There was much debate about the safety of dribbling onto a LFD or via a funnel etc but surely it should be as easy to run a swab around the inside of the mouth as it is inside the front of each nostril?
I’m sure there were many published results claiming saliva to be acceptable. So does anyone know what work needs to be done by Avacta to satisfy authorities (Prof Deeks) that saliva can be used with LFD’s because it cannot be the collection method?

Yorkshire Post article by Greg Wright is a 3 days old copy and paste from the RNS. Nothing new sadly.

Thanks for sharing the full tender document AgentB. I found this statement of particular interest in the Award section:

“ 8.5.2 In any case, each of the suppliers in the highest 5 ranking positions will be awarded a maximum of 40% of the total tender volume
8.5.3 Should the top 5 ranking suppliers not be able to fulfil the required volume, we would award additional suppliers based on the ranking order, each of which could get a maximum of 15% of the total volume”

192 million tests to be supplied from Jan to March 2021 so 40% of that is 76.8 million test. Price to be between £2 to £6 max so average of £3 gives max value per supplier of approx £230M. Hopefully we will be one of the 5 selected and if so our best performing S&S should see a return of £230M - and that’s just UK supply of course.

I have been considering the implications of something Alistair Smith said during his web presentation yesterday https://avacta.wistia.com/medias/30w6vgnvmg (2 min 50 secs in) and now ask if the more experienced holders here might be able to shed some light on this for me.

AS said "We now have test devices with analytical sensitivity better than 300pg/ml of spike protein. I'm not going to give a precise figure on that because it is COMMERCIALLY SENSITIVE but it is within the range we expect in clinical samples."

The legal definition of commercially sensitive is " . . . . information relating to the Supplier (Avacta), its IPR or its business or which the Supplier has indicated to the Customer (BBI or Govt?) that, if disclosed by the Customer, would cause Avacta significant commercial disadvantage or material financial loss.”

How would the release of the precise analytical sensitivity of Avacta's test device cause Avacta significant commercial disadvantage or material financial loss? Surely this means AS either knows or believes his lateral flow device is better than his competitors. Some may consider this obvious but it suggests to me that AS knows he has a commercial advantage and is intent on exploiting it. He said this only yesterday so clearly believes significant orders are there to be won. GLA